Olivier Wouters
@ojwouters
Followers
517
Following
602
Statuses
167
Associate Professor @BrownHSPP Affiliate Faculty @PORTAL_Research Investigating global disparities in access to medicines
London, England
Joined June 2015
In our new @NEJM piece, we explore how the US came to spend billions of $$ over the past decade on a medicine first approved more than 40 years ago @wbfeldman has put together a nice summary of our proposed solutions @SeanTu2 @PORTAL_Research
1/ In 2008, @US_FDA phased out #albuterol inhalers w/ ozone-depleting CFCs, including several generics. Since then, brand-name firms have reaped $14 billion in sales on albuterol products--though the active ingredient went off #patent in 1989! 🧵👇
1
4
15
8/ Join Health Affairs’ Jessica Bylander (@jebylander) and me for a virtual “journal club” on October 21st at 11am EDT (4pm BST) where we’ll talk about the paper. Message me if you’d like to attend!
0
0
1
RT @paimadhu: We knew this already, but new study by @ojwouters & Jouni Kuha confirms that it takes a long time for new medicines to reach…
0
16
0
RT @PeterNeumann11: Thanks to @ojwouters for visiting @TuftsCEVR and a truly excellent presentation on drug R&D expenditures, #HTA policies…
0
4
0
RT @KNVokinger: New piece: Drugs increasingly approved for many indications. Findings indicate substantially lower R&D costs for supplement…
0
9
0
RT @kjmeetswrld: 🚨New @TheLancetOncol research was published right before #ASCO23 with a team of talented co-authors from around the 🌏, l…
0
9
0
RT @LaiaMaynou: In our new publication at Research Policy with @abanalestanol, @JofreBonet, Giulia Iori, Michele Tumminello and Pietro Vass…
0
6
0
RT @bmj_latest: Regulated information sources for anticancer drugs in Europe fail to address the information needs of patients, finds study…
0
6
0
RT @LSEHealthPolicy: Want to learn more about pharmaceutical policy and economics? In a new report commissioned by @HealthFdn #REAL Centr…
0
17
0
RT @LSEHealthPolicy: In new @JAMAHealthForum paper, @LSEHealthPolicy’s Huseyin Naci and @robinjforrest_ examine the insurer restrictions on…
0
5
0
Fascinating deep dive into the AstraZeneca-Fiocruz partnership that saw Brazil produce millions of doses of the AZ vaccine. Offers lots of insights into vaccine technology transfer @Emassard, Ken Shadlen (@LSE_ID) and Helena Moraes Achcar (@FGV_EAESP)
0
0
7
RT @bmj_latest: High drug prices are not justified by industry’s research and development spending, argue @Aris_Angelis and colleagues. Fr…
0
57
0
RT @Aris_Angelis: Are high drug prices justified? In our @bmj_latest Analysis we investigate the spending of the 15 largest biopharmaceuti…
0
17
0
RT @wbfeldman: From 2000-2021, manufacturers earned $111 billion on brand-name #inhalers in the US AFTER patents on their active ingredient…
0
66
0